 | • レポートコード：MRC2-11QY01513 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は高コレステロール血症薬のグローバル市場について調査・分析したレポートです。種類別（スタチン、非スタチン）市場規模、用途別（FH、非FH）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別高コレステロール血症薬の競争状況、市場シェア ・世界の高コレステロール血症薬市場：種類別市場規模 2015年-2020年（スタチン、非スタチン） ・世界の高コレステロール血症薬市場：種類別市場規模予測 2021年-2026年（スタチン、非スタチン） ・世界の高コレステロール血症薬市場：用途別市場規模 2015年-2020年（FH、非FH） ・世界の高コレステロール血症薬市場：用途別市場規模予測 2021年-2026年（FH、非FH） ・北米の高コレステロール血症薬市場分析：米国、カナダ ・ヨーロッパの高コレステロール血症薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの高コレステロール血症薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の高コレステロール血症薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの高コレステロール血症薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Merck、Pfizer、Aegerion Pharmaceuticals、AbbVie、Sanofi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hypercholesterolemia also known as high cholesterol, is the presence of excess levels of cholesterol in the body that increases a risk of developing heart attack, and stroke.
Changes in lifestyle pattern such as the adoption of a sedentary form, increasing rate alcohol consumption and change in dietary pattern are driving the growth of hypercholesterolemia drugs market. For the purpose of the study hypercholesterolemia drugs market is segmented on the basis of drug class such as HMG-CoA reductase inhibitors/ statins, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, others drugs. It is studied that, currently HMG-CoA reductase inhibitors/ statins held largest market share because statins are commonly prescribed drug class due to their safety and effectiveness in lowering cholesterol.
Market Analysis and Insights: Global Hypercholesterolemia Drugs Market
The global Hypercholesterolemia Drugs market size is projected to reach US$ 14200 million by 2026, from US$ 13400 million in 2020, at a CAGR of 5.4%% during 2021-2026.
Global Hypercholesterolemia Drugs Scope and Market Size
Hypercholesterolemia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hypercholesterolemia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hypercholesterolemia Drugs market is segmented into
Statins
Non-Statins
Segment by Application, the Hypercholesterolemia Drugs market is segmented into
FH
Non-FH
Regional and Country-level Analysis
The Hypercholesterolemia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hypercholesterolemia Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hypercholesterolemia Drugs Market Share Analysis
Hypercholesterolemia Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hypercholesterolemia Drugs business, the date to enter into the Hypercholesterolemia Drugs market, Hypercholesterolemia Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
Merck
Pfizer
Aegerion Pharmaceuticals
AbbVie
Sanofi
…
1 Study Coverage
1.1 Hypercholesterolemia Drugs Product Introduction
1.2 Market Segments
1.3 Key Hypercholesterolemia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hypercholesterolemia Drugs Market Size Growth Rate by Type
1.4.2 Statins
1.4.3 Non-Statins
1.5 Market by Application
1.5.1 Global Hypercholesterolemia Drugs Market Size Growth Rate by Application
1.5.2 FH
1.5.3 Non-FH
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hypercholesterolemia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hypercholesterolemia Drugs Revenue 2015-2026
2.1.2 Global Hypercholesterolemia Drugs Sales 2015-2026
2.2 Global Hypercholesterolemia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hypercholesterolemia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hypercholesterolemia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hypercholesterolemia Drugs Competitor Landscape by Players
3.1 Hypercholesterolemia Drugs Sales by Manufacturers
3.1.1 Hypercholesterolemia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hypercholesterolemia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hypercholesterolemia Drugs Revenue by Manufacturers
3.2.1 Hypercholesterolemia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hypercholesterolemia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hypercholesterolemia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hypercholesterolemia Drugs Revenue in 2019
3.2.5 Global Hypercholesterolemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hypercholesterolemia Drugs Price by Manufacturers
3.4 Hypercholesterolemia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hypercholesterolemia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hypercholesterolemia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hypercholesterolemia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hypercholesterolemia Drugs Market Size by Type (2015-2020)
4.1.1 Global Hypercholesterolemia Drugs Sales by Type (2015-2020)
4.1.2 Global Hypercholesterolemia Drugs Revenue by Type (2015-2020)
4.1.3 Hypercholesterolemia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hypercholesterolemia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hypercholesterolemia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hypercholesterolemia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hypercholesterolemia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hypercholesterolemia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hypercholesterolemia Drugs Market Size by Application (2015-2020)
5.1.1 Global Hypercholesterolemia Drugs Sales by Application (2015-2020)
5.1.2 Global Hypercholesterolemia Drugs Revenue by Application (2015-2020)
5.1.3 Hypercholesterolemia Drugs Price by Application (2015-2020)
5.2 Hypercholesterolemia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hypercholesterolemia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hypercholesterolemia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hypercholesterolemia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hypercholesterolemia Drugs by Country
6.1.1 North America Hypercholesterolemia Drugs Sales by Country
6.1.2 North America Hypercholesterolemia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hypercholesterolemia Drugs Market Facts & Figures by Type
6.3 North America Hypercholesterolemia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hypercholesterolemia Drugs by Country
7.1.1 Europe Hypercholesterolemia Drugs Sales by Country
7.1.2 Europe Hypercholesterolemia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hypercholesterolemia Drugs Market Facts & Figures by Type
7.3 Europe Hypercholesterolemia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hypercholesterolemia Drugs by Region
8.1.1 Asia Pacific Hypercholesterolemia Drugs Sales by Region
8.1.2 Asia Pacific Hypercholesterolemia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hypercholesterolemia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hypercholesterolemia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hypercholesterolemia Drugs by Country
9.1.1 Latin America Hypercholesterolemia Drugs Sales by Country
9.1.2 Latin America Hypercholesterolemia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hypercholesterolemia Drugs Market Facts & Figures by Type
9.3 Central & South America Hypercholesterolemia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hypercholesterolemia Drugs by Country
10.1.1 Middle East and Africa Hypercholesterolemia Drugs Sales by Country
10.1.2 Middle East and Africa Hypercholesterolemia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hypercholesterolemia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hypercholesterolemia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Hypercholesterolemia Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description and Business Overview
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Hypercholesterolemia Drugs Products Offered
11.2.5 Merck Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Hypercholesterolemia Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Aegerion Pharmaceuticals
11.4.1 Aegerion Pharmaceuticals Corporation Information
11.4.2 Aegerion Pharmaceuticals Description and Business Overview
11.4.3 Aegerion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Aegerion Pharmaceuticals Hypercholesterolemia Drugs Products Offered
11.4.5 Aegerion Pharmaceuticals Related Developments
11.5 AbbVie
11.5.1 AbbVie Corporation Information
11.5.2 AbbVie Description and Business Overview
11.5.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AbbVie Hypercholesterolemia Drugs Products Offered
11.5.5 AbbVie Related Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Description and Business Overview
11.6.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi Hypercholesterolemia Drugs Products Offered
11.6.5 Sanofi Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Hypercholesterolemia Drugs Products Offered
11.1.5 AstraZeneca Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hypercholesterolemia Drugs Market Estimates and Projections by Region
12.1.1 Global Hypercholesterolemia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hypercholesterolemia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hypercholesterolemia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hypercholesterolemia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hypercholesterolemia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hypercholesterolemia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hypercholesterolemia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hypercholesterolemia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hypercholesterolemia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hypercholesterolemia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hypercholesterolemia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hypercholesterolemia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hypercholesterolemia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hypercholesterolemia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hypercholesterolemia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hypercholesterolemia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hypercholesterolemia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hypercholesterolemia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hypercholesterolemia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hypercholesterolemia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hypercholesterolemia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hypercholesterolemia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hypercholesterolemia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hypercholesterolemia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hypercholesterolemia Drugs Market Segments
Table 2. Ranking of Global Top Hypercholesterolemia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hypercholesterolemia Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Statins
Table 5. Major Manufacturers of Non-Statins
Table 6. Global Hypercholesterolemia Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 7. Global Hypercholesterolemia Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 8. Global Hypercholesterolemia Drugs Sales by Regions 2015-2020 (K MT)
Table 9. Global Hypercholesterolemia Drugs Sales Market Share by Regions (2015-2020)
Table 10. Global Hypercholesterolemia Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Hypercholesterolemia Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 12. Global Hypercholesterolemia Drugs Sales Share by Manufacturers (2015-2020)
Table 13. Global Hypercholesterolemia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Hypercholesterolemia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypercholesterolemia Drugs as of 2019)
Table 15. Hypercholesterolemia Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Hypercholesterolemia Drugs Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Hypercholesterolemia Drugs Price (2015-2020) (USD/MT)
Table 18. Hypercholesterolemia Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Hypercholesterolemia Drugs Product Type
Table 20. Date of International Manufacturers Enter into Hypercholesterolemia Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 23. Global Hypercholesterolemia Drugs Sales Share by Type (2015-2020)
Table 24. Global Hypercholesterolemia Drugs Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Hypercholesterolemia Drugs Revenue Share by Type (2015-2020)
Table 26. Hypercholesterolemia Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 27. Global Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 28. Global Hypercholesterolemia Drugs Sales Share by Application (2015-2020)
Table 29. North America Hypercholesterolemia Drugs Sales by Country (2015-2020) (K MT)
Table 30. North America Hypercholesterolemia Drugs Sales Market Share by Country (2015-2020)
Table 31. North America Hypercholesterolemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Hypercholesterolemia Drugs Revenue Market Share by Country (2015-2020)
Table 33. North America Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 34. North America Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Table 35. North America Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 36. North America Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Table 37. Europe Hypercholesterolemia Drugs Sales by Country (2015-2020) (K MT)
Table 38. Europe Hypercholesterolemia Drugs Sales Market Share by Country (2015-2020)
Table 39. Europe Hypercholesterolemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Hypercholesterolemia Drugs Revenue Market Share by Country (2015-2020)
Table 41. Europe Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 42. Europe Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Table 43. Europe Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 44. Europe Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Hypercholesterolemia Drugs Sales by Region (2015-2020) (K MT)
Table 46. Asia Pacific Hypercholesterolemia Drugs Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Hypercholesterolemia Drugs Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Hypercholesterolemia Drugs Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 50. Asia Pacific Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 52. Asia Pacific Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Table 53. Latin America Hypercholesterolemia Drugs Sales by Country (2015-2020) (K MT)
Table 54. Latin America Hypercholesterolemia Drugs Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Hypercholesterolemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Hypercholesterolemia Drugs Revenue Market Share by Country (2015-2020)
Table 57. Latin America Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 58. Latin America Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Table 59. Latin America Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 60. Latin America Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Hypercholesterolemia Drugs Sales by Country (2015-2020) (K MT)
Table 62. Middle East and Africa Hypercholesterolemia Drugs Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Hypercholesterolemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Hypercholesterolemia Drugs Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Hypercholesterolemia Drugs Sales by Type (2015-2020) (K MT)
Table 66. Middle East and Africa Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Hypercholesterolemia Drugs Sales by Application (2015-2020) (K MT)
Table 68. Middle East and Africa Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Table 69. AstraZeneca Corporation Information
Table 70. AstraZeneca Description and Major Businesses
Table 71. AstraZeneca Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. AstraZeneca Product
Table 73. AstraZeneca Recent Development
Table 74. Merck Corporation Information
Table 75. Merck Description and Major Businesses
Table 76. Merck Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Merck Product
Table 78. Merck Recent Development
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Major Businesses
Table 81. Pfizer Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. Pfizer Product
Table 83. Pfizer Recent Development
Table 84. Aegerion Pharmaceuticals Corporation Information
Table 85. Aegerion Pharmaceuticals Description and Major Businesses
Table 86. Aegerion Pharmaceuticals Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Aegerion Pharmaceuticals Product
Table 88. Aegerion Pharmaceuticals Recent Development
Table 89. AbbVie Corporation Information
Table 90. AbbVie Description and Major Businesses
Table 91. AbbVie Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. AbbVie Product
Table 93. AbbVie Recent Development
Table 94. Sanofi Corporation Information
Table 95. Sanofi Description and Major Businesses
Table 96. Sanofi Hypercholesterolemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Sanofi Product
Table 98. Sanofi Recent Development
Table 99. Global Hypercholesterolemia Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 100. Global Hypercholesterolemia Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 101. Global Hypercholesterolemia Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 102. Global Hypercholesterolemia Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 103. North America: Hypercholesterolemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 104. North America: Hypercholesterolemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Europe: Hypercholesterolemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 106. Europe: Hypercholesterolemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Asia Pacific: Hypercholesterolemia Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 108. Asia Pacific: Hypercholesterolemia Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 109. Latin America: Hypercholesterolemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 110. Latin America: Hypercholesterolemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Middle East and Africa: Hypercholesterolemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 112. Middle East and Africa: Hypercholesterolemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Market Risks
Table 116. Main Points Interviewed from Key Hypercholesterolemia Drugs Players
Table 117. Hypercholesterolemia Drugs Customers List
Table 118. Hypercholesterolemia Drugs Distributors List
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Hypercholesterolemia Drugs Product Picture
Figure 2. Global Hypercholesterolemia Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Statins Product Picture
Figure 4. Non-Statins Product Picture
Figure 5. Global Hypercholesterolemia Drugs Sales Market Share by Application in 2020 & 2026
Figure 6. FH
Figure 7. Non-FH
Figure 8. Hypercholesterolemia Drugs Report Years Considered
Figure 9. Global Hypercholesterolemia Drugs Market Size 2015-2026 (US$ Million)
Figure 10. Global Hypercholesterolemia Drugs Sales 2015-2026 (K MT)
Figure 11. Global Hypercholesterolemia Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Hypercholesterolemia Drugs Sales Market Share by Region (2015-2020)
Figure 13. Global Hypercholesterolemia Drugs Sales Market Share by Region in 2019
Figure 14. Global Hypercholesterolemia Drugs Revenue Market Share by Region (2015-2020)
Figure 15. Global Hypercholesterolemia Drugs Revenue Market Share by Region in 2019
Figure 16. Global Hypercholesterolemia Drugs Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Hypercholesterolemia Drugs Revenue in 2019
Figure 18. Hypercholesterolemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Hypercholesterolemia Drugs Sales Market Share by Type (2015-2020)
Figure 20. Global Hypercholesterolemia Drugs Sales Market Share by Type in 2019
Figure 21. Global Hypercholesterolemia Drugs Revenue Market Share by Type (2015-2020)
Figure 22. Global Hypercholesterolemia Drugs Revenue Market Share by Type in 2019
Figure 23. Global Hypercholesterolemia Drugs Market Share by Price Range (2015-2020)
Figure 24. Global Hypercholesterolemia Drugs Sales Market Share by Application (2015-2020)
Figure 25. Global Hypercholesterolemia Drugs Sales Market Share by Application in 2019
Figure 26. Global Hypercholesterolemia Drugs Revenue Market Share by Application (2015-2020)
Figure 27. Global Hypercholesterolemia Drugs Revenue Market Share by Application in 2019
Figure 28. North America Hypercholesterolemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 29. North America Hypercholesterolemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Hypercholesterolemia Drugs Sales Market Share by Country in 2019
Figure 31. North America Hypercholesterolemia Drugs Revenue Market Share by Country in 2019
Figure 32. U.S. Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 33. U.S. Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 35. Canada Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Hypercholesterolemia Drugs Market Share by Type in 2019
Figure 37. North America Hypercholesterolemia Drugs Market Share by Application in 2019
Figure 38. Europe Hypercholesterolemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 39. Europe Hypercholesterolemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Hypercholesterolemia Drugs Sales Market Share by Country in 2019
Figure 41. Europe Hypercholesterolemia Drugs Revenue Market Share by Country in 2019
Figure 42. Germany Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 43. Germany Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 45. France Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 47. U.K. Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 49. Italy Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 51. Russia Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Hypercholesterolemia Drugs Market Share by Type in 2019
Figure 53. Europe Hypercholesterolemia Drugs Market Share by Application in 2019
Figure 54. Asia Pacific Hypercholesterolemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 55. Asia Pacific Hypercholesterolemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Hypercholesterolemia Drugs Sales Market Share by Region in 2019
Figure 57. Asia Pacific Hypercholesterolemia Drugs Revenue Market Share by Region in 2019
Figure 58. China Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 59. China Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 61. Japan Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 63. South Korea Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 65. India Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 67. Australia Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 69. Taiwan Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 71. Indonesia Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 73. Thailand Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 75. Malaysia Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 77. Philippines Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 79. Vietnam Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Hypercholesterolemia Drugs Market Share by Type in 2019
Figure 81. Asia Pacific Hypercholesterolemia Drugs Market Share by Application in 2019
Figure 82. Latin America Hypercholesterolemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 83. Latin America Hypercholesterolemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Hypercholesterolemia Drugs Sales Market Share by Country in 2019
Figure 85. Latin America Hypercholesterolemia Drugs Revenue Market Share by Country in 2019
Figure 86. Mexico Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 87. Mexico Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 89. Brazil Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 91. Argentina Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Hypercholesterolemia Drugs Market Share by Type in 2019
Figure 93. Latin America Hypercholesterolemia Drugs Market Share by Application in 2019
Figure 94. Middle East and Africa Hypercholesterolemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 95. Middle East and Africa Hypercholesterolemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Hypercholesterolemia Drugs Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Hypercholesterolemia Drugs Revenue Market Share by Country in 2019
Figure 98. Turkey Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 99. Turkey Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 101. Saudi Arabia Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Hypercholesterolemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 103. U.A.E Hypercholesterolemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Hypercholesterolemia Drugs Market Share by Type in 2019
Figure 105. Middle East and Africa Hypercholesterolemia Drugs Market Share by Application in 2019
Figure 106. North America Hypercholesterolemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 107. North America Hypercholesterolemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 108. Europe Hypercholesterolemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 109. Europe Hypercholesterolemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Asia Pacific Hypercholesterolemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 111. Asia Pacific Hypercholesterolemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Latin America Hypercholesterolemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. Latin America Hypercholesterolemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Middle East and Africa Hypercholesterolemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Middle East and Africa Hypercholesterolemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Porter's Five Forces Analysis
Figure 117. Channels of Distribution
Figure 118. Distributors Profiles
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed
高コレステロール血症治療の世界市場（～2026年） Hypercholesterolemia is a genetic disorder characterized by very high levels of cholesterol in the blood. Hypercholesterolemia, also termed as dyslipidemia, is a form of hyperlipidemia and hyperlipoproteinemia in the body. Presence of low-density Lipoprotein Cholesterol (LDL-C) or bad cholesterol in…- ヘテロ接合性家族性高コレステロール血症薬の世界市場（～2026年） Market Analysis and Insights: Global Heterozygous Familial Hypercholesterolemia Drug Market The global Heterozygous Familial Hypercholesterolemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Heterozygous Famili…
- ホモ接合性家族性高コレステロール血症治療の世界市場（～2026年） Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Treatment Market The global Homozygous Familial Hypercholesterolemia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Homozygous Fa…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…